ENCell
ENCell (KOSDAQ: 456070) is a South Korea-based GMP contract manufacturer specializing in cell and gene therapy production, including NK cell therapies, for biotech and pharmaceutical clients pursuing clinical development in the US and Asia-Pacific.
- Company typePrivate
- Founded2018
- HeadquartersSeoul, South Korea
- Headcount101–250
- GTM typeB2B
- OfferingServices
What ENCell does
ENCell Co., Ltd. (KOSDAQ: 456070) is a South Korea-based contract development and manufacturing organization (CDMO) founded in 2018 and headquartered in Seoul. The company provides Good Manufacturing Practice (GMP) manufacturing services for advanced therapy developers, with particular specialization in cell and gene therapy production. Its core offering includes clinical trial material manufacturing for NK cell therapies and gene therapies, exemplified by its contract manufacturing agreement with Ingenium Therapeutics for gengleucel—an FDA orphan drug-designated NK cell therapy candidate for acute myeloid leukemia—and its gene therapy-focused collaboration with US-based Andelyn Biosciences.
The company's technology platform centers on compliant, specialized manufacturing processes for living-cell products and regenerative therapies. ENCell has invested in capabilities spanning NK cell therapy production and advanced regenerative/stem cell-based applications, including anti-aging indications. Its partnership with Andelyn creates a 'dual hemisphere' manufacturing network linking facilities in the United States and Asia-Pacific, enabling clients to run parallel regional manufacturing for clinical trials and reducing cross-border regulatory and logistical friction.
ENCell generates revenue through B2B contract manufacturing agreements with biotech and pharmaceutical companies developing cell and gene therapies. Pricing is quote-based and not publicly disclosed, consistent with project-driven CDMO economics. The company targets a horizontal customer segment—biotech and pharma sponsors requiring GMP manufacturing for clinical-stage advanced therapies—and is beginning to extend into proprietary regenerative/anti-aging applications funded by its December 2025 capital raise of approximately KRW 22.5 billion (~USD 15.3 million), led by NH Investment & Securities.
ENCell firmographics
Firmographics- Name
- ENCell
- Legal name
- ENCell Co., Ltd.
- Website
- https://encellinc.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- ENCell (KOSDAQ: 456070) is a South Korea-based GMP contract manufacturer specializing in cell and gene therapy production, including NK cell therapies, for biotech and pharmaceutical clients pursuing clinical development in the US and Asia-Pacific.
- Ownership category
- akta.pro rank
ENCell industry classification
Industry- Product category
- Biopharmaceutical CDMO
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where ENCell is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Markets served
ENCell business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing Services: ENCell generates revenue through contract manufacturing agreements with biotech and pharmaceutical companies for production of clinical trial materials, cell therapies, and gene therapy products under GMP conditions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
ENCell product offering
Product offeringCore offering
ENCell is a contract development and manufacturing organization (CDMO) specializing in GMP (Good Manufacturing Practice) production of clinical trial materials for cell and gene therapy developers. The company manufactures clinical-stage cell therapies such as NK cell therapy candidates (including gengleucel for acute myeloid leukemia) and provides a strategic dual-hemisphere manufacturing network bridging the United States and Asia-Pacific regions through its partnership with Andelyn Biosciences.
Differentiator
Problem solved
Functional benefit
Products and services
- GMP Contract Manufacturing Services
- NK Cell Therapy Manufacturing
- Dual-Hemisphere Cell and Gene Therapy Manufacturing
- Advanced Regenerative Therapy Development
Quantifiable outcome
- Manufacturing partnership enables in-country manufacturing for local clinical trials and patient populations
Companies that use ENCell
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
ENCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ENCell partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Ingenium TherapeuticscoreENCell signed a contract manufacturing agreement with Ingenium Therapeutics to produce clinical trial materials for gengleucel, an NK cell therapy candidate for acute myeloid leukemia, supporting U.S. clinical development. The therapy received FDA orphan drug designation.
- Andelyn BiosciencescoreAndelyn Biosciences and ENCell signed a Collaboration Agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific regions for gene therapy development. The partnership combines both companies' GMP manufacturing facilities, technical expertise, and regional networks to enable a streamlined 'dual hemisphere' workflow that reduces regulatory and logistical complexities of international expansion.
Scale indicators3 records
Recent moves4 records
Expansion highlights4 records
ENCell competitors and assessment
Company assessmentDirect peers
- Andelyn Biosciences: US-based cell and gene therapy CDMO with GMP manufacturing capabilities. Direct peer and strategic partner; ENCell's dual-hemisphere model is built around Andelyn's US facility as the North American counterpart to ENCell's APAC operations.
Broad incumbents
- Samsung Biologics: Korea's largest biopharmaceutical CDMO offering contract manufacturing for biologics and advanced therapies. As a domestic incumbent with significantly greater scale, Samsung Biologics competes for the same Korean and global cell/gene therapy contracts.
- SK Pharmteco: Korean-headquartered CDMO providing small-molecule API, biologics, and cell/gene therapy manufacturing services. Comparable end-market and geography; competes for advanced therapy manufacturing contracts in the APAC region.
- Lonza: Global leader in cell and gene therapy CDMO services with extensive GMP manufacturing capacity. Sets pricing benchmarks and capability expectations for advanced therapy CDMOs worldwide, including for NK cell therapy production.
- AGC Biologics: Global CDMO offering cell and gene therapy manufacturing services alongside biologics. Competes for clinical-stage cell therapy manufacturing contracts and has comparable GMP capabilities to ENCell.
- WuXi Advanced Therapies: Cell and gene therapy CDMO unit of WuXi AppTec providing process development and GMP manufacturing. Significant scale and global footprint make it a direct competitor for advanced therapy manufacturing contracts.
- Catalent: Major global CDMO with cell and gene therapy capabilities including viral vector and cell therapy manufacturing. Comparable service offerings for clinical-stage cell therapy developers.
Regional players
- Celltrion: Korean biopharmaceutical company with manufacturing capabilities and growing presence in biosimilars and novel biologics. Comparable Korean-domiciled biomanufacturing competitor focused on domestic and select international markets.
Emerging players
- Vineti: Specialized technology and services provider for cell and gene therapy supply chain management. Adjacent peer in the cell therapy ecosystem with comparable focus on enabling clinical and commercial cell therapy workflows.
- RoslinCT: Cell therapy CDMO specializing in GMP manufacturing for clinical and commercial cell therapies including allogeneic platforms. Comparable scale and specialization to ENCell for cell therapy manufacturing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
ENCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
ENCell leadership team
Management profileNumber of profiles
ENCell funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ENCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ENCell
What does ENCell do?
ENCell is a contract development and manufacturing organization (CDMO) specializing in GMP (Good Manufacturing Practice) production of clinical trial materials for cell and gene therapy developers. The company manufactures clinical-stage cell therapies such as NK cell therapy candidates (including gengleucel for acute myeloid leukemia) and provides a strategic dual-hemisphere manufacturing network bridging the United States and Asia-Pacific regions through its partnership with Andelyn Biosciences.
Is ENCell a public or private company?
ENCell is a private company. It is classified as public and is currently operating.
When was ENCell founded?
ENCell was founded in 2018. It employs 101 to 250 people.
Where is ENCell based?
ENCell is headquartered in Seoul, South Korea, in the Asia region.
How does ENCell make money?
One revenue line is on record: contract Manufacturing Services.
Who are ENCell's main competitors?
Andelyn Biosciences is listed as a direct peer. Broad incumbents are Samsung Biologics, SK Pharmteco, Lonza, AGC Biologics, WuXi Advanced Therapies and Catalent. Celltrion is listed as a regional player. Emerging players are Vineti and RoslinCT.
Does ENCell have an API?
No public API is recorded for ENCell.
What industry is ENCell in?
ENCell's product category is Biopharmaceutical CDMO. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 32541 and its SIC code is 8731.